Selected research
Industry Research
Mucopolysaccharidosis II Industry Research Report 2026
Market perspective
The global Mucopolysaccharidosis II market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mucopolysaccharidosis II is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mucopolysaccharidosis II is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mucopolysaccharidosis II is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mucopolysaccharidosis II include Takeda, Sangamo BioSciences, Inc., RegenxBio Inc., Laboratorios Del Dr. Esteve S.A., JCR Pharmaceuticals Co., Ltd., Inventiva, Green Cross Corporation, Bioasis Technologies Inc. and ArmaGen Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mucopolysaccharidosis II market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mucopolysaccharidosis II Market by Company
Takeda
Sangamo BioSciences, Inc.
RegenxBio Inc.
Laboratorios Del Dr. Esteve S.A.
JCR Pharmaceuticals Co., Ltd.
Inventiva
Green Cross Corporation
Bioasis Technologies Inc.
ArmaGen Inc.
AngioChem Inc.
Alexion Pharmaceuticals, Inc.
Mucopolysaccharidosis II Segment by Type
AGT-182
DUOC-01
EGT-301
JR-032
JR-141
Others
Mucopolysaccharidosis II Segment by Application
Clinic
Hospital
Research Center
Others
Mucopolysaccharidosis II Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mucopolysaccharidosis II market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mucopolysaccharidosis II and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mucopolysaccharidosis II.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mucopolysaccharidosis II manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mucopolysaccharidosis II by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mucopolysaccharidosis II in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AGT-182
- DUOC-01
- EGT-301
- JR-032
- JR-141
- Others
Applications
- Clinic
- Hospital
- Research Center
- Others
Companies covered
- Takeda
- Sangamo BioSciences, Inc.
- RegenxBio Inc.
- Laboratorios Del Dr. Esteve S.A.
- JCR Pharmaceuticals Co., Ltd.
- Inventiva
- Green Cross Corporation
- Bioasis Technologies Inc.
- ArmaGen Inc.
- AngioChem Inc.
- Alexion Pharmaceuticals, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mucopolysaccharidosis II Market Size (2021-2032)
- 2.2.2 Global Mucopolysaccharidosis II Sales (2021-2032)
- 2.2.3 Global Mucopolysaccharidosis II Market Average Price (2021-2032)
- 2.3 Mucopolysaccharidosis II by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AGT-182
- 2.3.3 DUOC-01
- 2.3.4 EGT-301
- 2.3.5 JR-032
- 2.3.6 JR-141
- 2.3.7 Others
- 2.4 Mucopolysaccharidosis II by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Research Center
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mucopolysaccharidosis II Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mucopolysaccharidosis II Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Mucopolysaccharidosis II Revenue of Manufacturers (2021-2026)
- 3.4 Global Mucopolysaccharidosis II Average Price by Manufacturers (2021-2026)
- 3.5 Global Mucopolysaccharidosis II Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mucopolysaccharidosis II, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mucopolysaccharidosis II, Product Type & Application
- 3.8 Global Manufacturers of Mucopolysaccharidosis II, Established Date
- 3.9 Global Mucopolysaccharidosis II Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Mucopolysaccharidosis II Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Sangamo BioSciences, Inc.
- 4.2.1 Sangamo BioSciences, Inc. Company Information
- 4.2.2 Sangamo BioSciences, Inc. Business Overview
- 4.2.3 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Product Portfolio
- 4.2.5 Sangamo BioSciences, Inc. Recent Developments
- 4.3 RegenxBio Inc.
- 4.3.1 RegenxBio Inc. Company Information
- 4.3.2 RegenxBio Inc. Business Overview
- 4.3.3 RegenxBio Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 RegenxBio Inc. Mucopolysaccharidosis II Product Portfolio
- 4.3.5 RegenxBio Inc. Recent Developments
- 4.4 Laboratorios Del Dr. Esteve S.A.
- 4.4.1 Laboratorios Del Dr. Esteve S.A. Company Information
- 4.4.2 Laboratorios Del Dr. Esteve S.A. Business Overview
- 4.4.3 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Product Portfolio
- 4.4.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
- 4.5 JCR Pharmaceuticals Co., Ltd.
- 4.5.1 JCR Pharmaceuticals Co., Ltd. Company Information
- 4.5.2 JCR Pharmaceuticals Co., Ltd. Business Overview
- 4.5.3 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Product Portfolio
- 4.5.5 JCR Pharmaceuticals Co., Ltd. Recent Developments
- 4.6 Inventiva
- 4.6.1 Inventiva Company Information
- 4.6.2 Inventiva Business Overview
- 4.6.3 Inventiva Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Inventiva Mucopolysaccharidosis II Product Portfolio
- 4.6.5 Inventiva Recent Developments
- 4.7 Green Cross Corporation
- 4.7.1 Green Cross Corporation Company Information
- 4.7.2 Green Cross Corporation Business Overview
- 4.7.3 Green Cross Corporation Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Green Cross Corporation Mucopolysaccharidosis II Product Portfolio
- 4.7.5 Green Cross Corporation Recent Developments
- 4.8 Bioasis Technologies Inc.
- 4.8.1 Bioasis Technologies Inc. Company Information
- 4.8.2 Bioasis Technologies Inc. Business Overview
- 4.8.3 Bioasis Technologies Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bioasis Technologies Inc. Mucopolysaccharidosis II Product Portfolio
- 4.8.5 Bioasis Technologies Inc. Recent Developments
- 4.9 ArmaGen Inc.
- 4.9.1 ArmaGen Inc. Company Information
- 4.9.2 ArmaGen Inc. Business Overview
- 4.9.3 ArmaGen Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 ArmaGen Inc. Mucopolysaccharidosis II Product Portfolio
- 4.9.5 ArmaGen Inc. Recent Developments
- 4.10 AngioChem Inc.
- 4.10.1 AngioChem Inc. Company Information
- 4.10.2 AngioChem Inc. Business Overview
- 4.10.3 AngioChem Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AngioChem Inc. Mucopolysaccharidosis II Product Portfolio
- 4.10.5 AngioChem Inc. Recent Developments
- 4.11 Alexion Pharmaceuticals, Inc.
- 4.11.1 Alexion Pharmaceuticals, Inc. Company Information
- 4.11.2 Alexion Pharmaceuticals, Inc. Business Overview
- 4.11.3 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Product Portfolio
- 4.11.5 Alexion Pharmaceuticals, Inc. Recent Developments
5 Global Mucopolysaccharidosis II Market Scenario by Region
- 5.1 Global Mucopolysaccharidosis II Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mucopolysaccharidosis II Sales by Region: 2021-2032
- 5.2.1 Global Mucopolysaccharidosis II Sales by Region: 2021-2026
- 5.2.2 Global Mucopolysaccharidosis II Sales by Region: 2027-2032
- 5.3 Global Mucopolysaccharidosis II Revenue by Region: 2021-2032
- 5.3.1 Global Mucopolysaccharidosis II Revenue by Region: 2021-2026
- 5.3.2 Global Mucopolysaccharidosis II Revenue by Region: 2027-2032
- 5.4 North America Mucopolysaccharidosis II Market Facts & Figures by Country
- 5.4.1 North America Mucopolysaccharidosis II Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mucopolysaccharidosis II Sales by Country (2021-2032)
- 5.4.3 North America Mucopolysaccharidosis II Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mucopolysaccharidosis II Market Facts & Figures by Country
- 5.5.1 Europe Mucopolysaccharidosis II Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mucopolysaccharidosis II Sales by Country (2021-2032)
- 5.5.3 Europe Mucopolysaccharidosis II Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mucopolysaccharidosis II Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mucopolysaccharidosis II Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mucopolysaccharidosis II Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mucopolysaccharidosis II Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mucopolysaccharidosis II Market Facts & Figures by Country
- 5.7.1 South America Mucopolysaccharidosis II Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mucopolysaccharidosis II Sales by Country (2021-2032)
- 5.7.3 South America Mucopolysaccharidosis II Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Mucopolysaccharidosis II Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mucopolysaccharidosis II Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mucopolysaccharidosis II Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mucopolysaccharidosis II Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mucopolysaccharidosis II Sales by Type (2021-2032)
- 6.1.1 Global Mucopolysaccharidosis II Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Mucopolysaccharidosis II Sales Market Share by Type (2021-2032)
- 6.2 Global Mucopolysaccharidosis II Revenue by Type (2021-2032)
- 6.2.1 Global Mucopolysaccharidosis II Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mucopolysaccharidosis II Revenue Market Share by Type (2021-2032)
- 6.3 Global Mucopolysaccharidosis II Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mucopolysaccharidosis II Sales by Application (2021-2032)
- 7.1.1 Global Mucopolysaccharidosis II Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Mucopolysaccharidosis II Sales Market Share by Application (2021-2032)
- 7.2 Global Mucopolysaccharidosis II Revenue by Application (2021-2032)
- 7.2.1 Global Mucopolysaccharidosis II Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mucopolysaccharidosis II Revenue Market Share by Application (2021-2032)
- 7.3 Global Mucopolysaccharidosis II Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mucopolysaccharidosis II Value Chain Analysis
- 8.1.1 Mucopolysaccharidosis II Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mucopolysaccharidosis II Production Mode & Process
- 8.2 Mucopolysaccharidosis II Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mucopolysaccharidosis II Distributors
- 8.2.3 Mucopolysaccharidosis II Customers
9 Global Mucopolysaccharidosis II Analyzing Market Dynamics
- 9.1 Mucopolysaccharidosis II Industry Trends
- 9.2 Mucopolysaccharidosis II Industry Drivers
- 9.3 Mucopolysaccharidosis II Industry Opportunities and Challenges
- 9.4 Mucopolysaccharidosis II Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst